Insomnia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Insomnia – Pipeline Review, H2 2017’, provides an overview of the Insomnia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Insomnia

The report reviews pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Insomnia therapeutics and enlists all their major and minor projects

The report assesses Insomnia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Insomnia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Insomnia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexza Pharmaceuticals Inc

Athenex Inc

Eisai Co Ltd

Evotec AG

Grupo Ferrer Internacional SA

Heptares Therapeutics Ltd

Idorsia Ltd

Intec Pharma Ltd

Intra-Cellular Therapies Inc

Johnson & Johnson

Leading BioSciences Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Reviva Pharmaceuticals Inc

Shionogi & Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Yangtze River Pharmaceutical Group

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Insomnia - Overview 6

Insomnia - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Insomnia - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Insomnia - Companies Involved in Therapeutics Development 22

Alexza Pharmaceuticals Inc 22

Athenex Inc 22

Eisai Co Ltd 22

Evotec AG 23

Grupo Ferrer Internacional SA 23

Heptares Therapeutics Ltd 24

Idorsia Ltd 24

Intec Pharma Ltd 24

Intra-Cellular Therapies Inc 25

Johnson & Johnson 25

Leading BioSciences Inc 26

Merck & Co Inc 26

Neurim Pharmaceuticals Ltd 27

Reviva Pharmaceuticals Inc 27

Shionogi & Co Ltd 28

Taisho Pharmaceutical Holdings Co Ltd 28

Yangtze River Pharmaceutical Group 29

Insomnia - Drug Profiles 30

(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile 30

ACT-541468 - Drug Profile 31

CB-2810 - Drug Profile 33

CY-18 - Drug Profile 34

CY-20 - Drug Profile 35

DORA-12 - Drug Profile 36

DRGT-73 - Drug Profile 37

Drug for Insomnia - Drug Profile 38

Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 39

EVT-201 - Drug Profile 40

HTL-6641 - Drug Profile 41

JNJ-48816274 - Drug Profile 42

LASSBio-785 - Drug Profile 43

LASSBio-786 - Drug Profile 44

lemborexant - Drug Profile 45

lorediplon - Drug Profile 47

lumateperone tosylate - Drug Profile 49

MK-8133 - Drug Profile 60

MLS-03 - Drug Profile 61

nebivolol - Drug Profile 62

NEO-1940 - Drug Profile 63

piromelatine - Drug Profile 64

S-117957 - Drug Profile 66

seltorexant - Drug Profile 67

Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile 72

Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile 73

Small Molecules to Agonize CB1 and CB2 for Autism, Dermatitis and Insomnia - Drug Profile 74

Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile 75

TS-142 - Drug Profile 76

UCM-765 - Drug Profile 77

zaleplon - Drug Profile 78

zaleplon - Drug Profile 79

zolpidem tartrate - Drug Profile 81

zolpidem tartrate - Drug Profile 82

Insomnia - Dormant Projects 83

Insomnia - Discontinued Products 85

Insomnia - Product Development Milestones 86

Featured News & Press Releases 86

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

List of Tables

Number of Products under Development for Insomnia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Insomnia – Pipeline by Alexza Pharmaceuticals Inc, H2 2017

Insomnia – Pipeline by Athenex Inc, H2 2017

Insomnia – Pipeline by Eisai Co Ltd, H2 2017

Insomnia – Pipeline by Evotec AG, H2 2017

Insomnia – Pipeline by Grupo Ferrer Internacional SA, H2 2017

Insomnia – Pipeline by Heptares Therapeutics Ltd, H2 2017

Insomnia – Pipeline by Idorsia Ltd, H2 2017

Insomnia – Pipeline by Intec Pharma Ltd, H2 2017

Insomnia – Pipeline by Intra-Cellular Therapies Inc, H2 2017

Insomnia – Pipeline by Johnson & Johnson, H2 2017

Insomnia – Pipeline by Leading BioSciences Inc, H2 2017

Insomnia – Pipeline by Merck & Co Inc, H2 2017

Insomnia – Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Insomnia – Pipeline by Reviva Pharmaceuticals Inc, H2 2017

Insomnia – Pipeline by Shionogi & Co Ltd, H2 2017

Insomnia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017

Insomnia – Pipeline by Yangtze River Pharmaceutical Group, H2 2017

Insomnia – Dormant Projects, H2 2017

Insomnia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Insomnia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Insomnia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports